New Brunswick, NJ - According to Emily Bader, of NJBIZ, “Johnson & Johnson announced Wednesday that it has agreed to acquire Novira Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of chronic hepatitis B."
"The acquisition includes Novira’s portfolio of novel antivirals, New Brunswick-based Johnson & Johnson said in a news release.
"We are excited about the prospect this acquisition offers to accelerate the development of curative treatments for people affected by chronic hepatitis B," William N. Hait, global head, research & development, Janssen Pharmaceutical Companies of Johnson & Johnson, said in a prepared statement. "NVR 3-778 (Novira’s lead novel antiviral candidate) offers the potential for efficient suppression of virus production and replication, which could help address the remaining unmet medical needs."
The transaction is expected to close in the fourth quarter of 2015. Financial terms of the deal were not disclosed.”
"We are excited about the prospect this acquisition offers to accelerate the development of curative treatments for people affected by chronic hepatitis B," William N. Hait, global head, research & development, Janssen Pharmaceutical Companies of Johnson & Johnson, said in a prepared statement. "NVR 3-778 (Novira’s lead novel antiviral candidate) offers the potential for efficient suppression of virus production and replication, which could help address the remaining unmet medical needs."
The transaction is expected to close in the fourth quarter of 2015. Financial terms of the deal were not disclosed.”
